Preservative-free steroid called methylprednisolone acetate

●      Contains Polyquad preservative, gentle on sensitive eyes No References

  • Lipner, M. A Clear-Eyed View of Preservatives in Tears. (2014, March). Retrieved from  https:///article-a-clear-eyed-view-of-preservatives-in-tears
  • Eye Health Statistics. (.). Retrieved from https:///newsroom/eye-health-statistics
  • Causes of Dry Eye Syndrome. (.). Retrieved from  http:///diseases-conditions/dry-eyes/basics/causes/con-20024129
  • What Causes Dry Eyes? (.). Retrieved from  http:///eye-health/eye-health-dry-eyes
David McMahon, MBA My name is David McMahon, MBA, Masters in Nutrition (Candidate) and I created this site to educate consumers like you about dry eye syndrome and related eye disorders. I welcome any and all questions related to your condition. You can discover the secret to how I cured my own dry eye syndrome.

It Should Be Emphasized that Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached. Situations that may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation, it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize oral anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. Increased GI effects with aspirin, other NSAIDs. Caution with aspirin in hypoprothrombinemia. May suppress reactions to skin tests.

Preservative-free steroid called methylprednisolone acetate

preservative-free steroid called methylprednisolone acetate


preservative-free steroid called methylprednisolone acetatepreservative-free steroid called methylprednisolone acetatepreservative-free steroid called methylprednisolone acetatepreservative-free steroid called methylprednisolone acetatepreservative-free steroid called methylprednisolone acetate